On May 15, 2025, Stephens & Co. reaffirmed its "Overweight" rating for 10x Genomics (TXG, Financial), maintaining its price target at $14.00. The analyst Mason Carrico has kept both the rating and the price target unchanged, signaling continued confidence in the stock's performance at the current valuation.
The rating issued by Stephens & Co. reflects an optimistic outlook for 10x Genomics (TXG, Financial), a company recognized for its innovative technologies in the field of genomics. With the price target remaining steady, investors can consider this a vote of confidence from the analyst firm.
The current price target of $14.00 aligns with the previous target, indicating no percentage change. This consistency suggests that Stephens & Co. believes in the potential of 10x Genomics (TXG, Financial) to meet its current market expectations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 14 analysts, the average target price for 10x Genomics Inc (TXG, Financial) is $13.25 with a high estimate of $26.00 and a low estimate of $6.50. The average target implies an upside of 49.72% from the current price of $8.85. More detailed estimate data can be found on the 10x Genomics Inc (TXG) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, 10x Genomics Inc's (TXG, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for 10x Genomics Inc (TXG, Financial) in one year is $39.30, suggesting a upside of 344.07% from the current price of $8.85. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the 10x Genomics Inc (TXG) Summary page.
